OBJECTIVE: To report trends and characteristics of long-term opioid use for non-cancer pain. METHODS: CONSORT (CONsortium to Study Opioid Risks and Trends) includes adult enrollees of two health plans serving over 1 per cent of the US population. Using automated data, we constructed episodes of opioid use between 1997 and 2005. We estimated age-sex standardized rates of opioid use episodes beginning in each year (incident) and on-going in each year (prevalent), and the per cent change in rates annualized (PCA) over the 9-year period. Long-term episodes were defined as > 90 days with 120+ days supply or 10+ opioid prescriptions in a given year. RESULTS: Over the study period, incident long-term use increased from 8.5 to 12.1 per 1000 at Group Health (GH) (6.0% PCA), and 6.3 to 8.6 per 1000 at Kaiser Permanente of Northern California (KPNC) (5.5% PCA). Prevalent long-term use doubled from 23.9 to 46.8 per 1000 at GH (8.5% PCA), and 21.5 to 39.2 per 1000 at KPNC (8.1% PCA). Non-Schedule II opioids were the most commonly used opioid among patients engaged in long-term opioid therapy, particularly at KPNC. Long-term use of Schedule II opioids also increased substantially at both health plans. Among prevalent long-term users in 2005, 28.6% at GH and 30.2% at KPNC were also regular users of sedative hypnotics. CONCLUSION: Long-term opioid therapy for non-cancer pain is increasingly prevalent, but the benefits and risks associated with such therapy are inadequately understood. Concurrent use of opioids and sedative-hypnotics was unexpectedly common and deserves further study. Copyright (c) 2009 John Wiley & Sons, Ltd.
OBJECTIVE: To report trends and characteristics of long-term opioid use for non-cancer pain. METHODS: CONSORT (CONsortium to Study Opioid Risks and Trends) includes adult enrollees of two health plans serving over 1 per cent of the US population. Using automated data, we constructed episodes of opioid use between 1997 and 2005. We estimated age-sex standardized rates of opioid use episodes beginning in each year (incident) and on-going in each year (prevalent), and the per cent change in rates annualized (PCA) over the 9-year period. Long-term episodes were defined as > 90 days with 120+ days supply or 10+ opioid prescriptions in a given year. RESULTS: Over the study period, incident long-term use increased from 8.5 to 12.1 per 1000 at Group Health (GH) (6.0% PCA), and 6.3 to 8.6 per 1000 at Kaiser Permanente of Northern California (KPNC) (5.5% PCA). Prevalent long-term use doubled from 23.9 to 46.8 per 1000 at GH (8.5% PCA), and 21.5 to 39.2 per 1000 at KPNC (8.1% PCA). Non-Schedule II opioids were the most commonly used opioid among patients engaged in long-term opioid therapy, particularly at KPNC. Long-term use of Schedule II opioids also increased substantially at both health plans. Among prevalent long-term users in 2005, 28.6% at GH and 30.2% at KPNC were also regular users of sedative hypnotics. CONCLUSION: Long-term opioid therapy for non-cancer pain is increasingly prevalent, but the benefits and risks associated with such therapy are inadequately understood. Concurrent use of opioids and sedative-hypnotics was unexpectedly common and deserves further study. Copyright (c) 2009 John Wiley & Sons, Ltd.
Authors: Eija Kalso; Laurie Allan; Paul L I Dellemijn; Clara C Faura; Wilfried K Ilias; Troels S Jensen; Serge Perrot; Leon H Plaghki; Michael Zenz Journal: Eur J Pain Date: 2003 Impact factor: 3.931
Authors: Denise M Boudreau; Mark P Doescher; J Elizabeth Jackson; Paul A Fishman; Barry G Saver Journal: Ann Pharmacother Date: 2004-05-18 Impact factor: 3.154
Authors: Judith Parsells Kelly; Suzanne F Cook; David W Kaufman; Theresa Anderson; Lynn Rosenberg; Allen A Mitchell Journal: Pain Date: 2008-03-14 Impact factor: 6.961
Authors: Lesley H Curtis; Jennifer Stoddard; Jasmina I Radeva; Steve Hutchison; Peter E Dans; Alan Wright; Raymond L Woosley; Kevin A Schulman Journal: Health Serv Res Date: 2006-06 Impact factor: 3.402
Authors: Richard A Epstein; William V Bobo; Peter R Martin; James A Morrow; Wei Wang; Rameela Chandrasekhar; William O Cooper Journal: Ann Epidemiol Date: 2013-08 Impact factor: 3.797
Authors: Cynthia I Campbell; Constance Weisner; Linda Leresche; G Thomas Ray; Kathleen Saunders; Mark D Sullivan; Caleb J Banta-Green; Joseph O Merrill; Michael J Silverberg; Denise Boudreau; Derek D Satre; Michael Von Korff Journal: Am J Public Health Date: 2010-08-19 Impact factor: 9.308
Authors: William C Becker; Kirsha Gordon; E Jennifer Edelman; Robert D Kerns; Stephen Crystal; James D Dziura; Lynn E Fiellin; Adam J Gordon; Joseph L Goulet; Amy C Justice; David A Fiellin Journal: AIDS Behav Date: 2016-03
Authors: Brian T Bateman; Sonia Hernandez-Diaz; James P Rathmell; John D Seeger; Michael Doherty; Michael A Fischer; Krista F Huybrechts Journal: Anesthesiology Date: 2014-05 Impact factor: 7.892